Alcon Inc.
0A0D.L
London Stock Exchange53.78
CHF
-0.03
- -
Alcon Inc.
0A0D.L
(London Stock Exchange)
Recent
price
53.78
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Alcon Inc is a Swiss-American global leader in eye care dedicated to providing innovative vision products that enhance quality of life by helping people see better. Founded in 1945 and headquartered in Geneva, Switzerland, with a major operational base in Fort Worth, Texas, Alcon operates in more than 60 countries and serves patients in over 140 countries. Its core business is organized into two primary segments: Surgical and Vision Care. The Surgical segment offers the industry’s most comprehensive line of ophthalmic surgical products, including advanced technologies and devices for cataract, retinal, and refractive surgeries, as well as advanced technology intraocular lenses (ATIOLs) to treat cataracts and refractive errors such as presbyopia and astigmatism. It also provides surgical solutions, advanced viscoelastics, surgical packs, and disposable products used in cataract and vitreoretinal surgery. The Vision Care segment manufactures and markets a wide range of contact lenses—daily disposable, reusable, and color-enhancing—and a broad portfolio of ocular health products including those for dry eye, ocular allergies, contact lens care, ocular vitamins, and redness relievers. In recent major developments during 2024 and 2025, Alcon obtained the CE Mark and introduced the Clareon Vivity intraocular lens (IOL) in Europe, featuring toric options and extended range with minimal halo risk. In the United States, Alcon launched the Clareon PanOptix Pro trifocal IOL with advanced optics and a preloaded delivery platform. Additionally, Alcon continues to expand its strategic footprint through ongoing investments in innovation and research and development, with a particular focus on breakthrough eye care technologies. The company is involved in a high-profile acquisition attempt of STAAR Surgical, reflecting its strategic expansion in the ophthalmic surgical device market. Alcon maintains a strong commitment to sustainable business practices and global eye health initiatives. Alcon operates as an independent publicly traded company since its spinoff from Novartis in 2019. It serves a diverse customer base of ophthalmologists, optometrists, surgical centers, and consumers worldwide. The company’s subsidiaries include Aerie Pharmaceuticals, which specializes in glaucoma and eye disease treatments, and WaveLight, which develops laser eye surgery technologies. Alcon’s leadership in the eye care industry is underpinned by a long heritage of innovation, a comprehensive product portfolio, and a global presence aimed at addressing a broad spectrum of eye diseases and conditions. It invests heavily in clinical research to support product advancements and improve patient outcomes.